GPC3 and hepatocellular carcinoma: A phase I clinical trial assessed the safety and immunogenicity of a DNA vaccine encoding the HCC-associated peptide GPC3, demonstrating good tolerability and GPC3-specific immune responses in a subset of patients (194).